Loading...
XKRX
001060
Market cap363mUSD
Jul 10, Last price  
25,000.00KRW
1D
5.49%
1Q
-22.36%
Jan 2017
-52.56%
Name

JW Pharmaceutical Corp

Chart & Performance

D1W1MN
XKRX:001060 chart
P/E
9.36
P/S
0.75
EPS
2,671.24
Div Yield, %
—
Shrs. gr., 5y
0.78%
Rev. gr., 5y
7.20%
Revenues
774.80b
+7.70%
385,010,282,000437,648,380,000455,146,860,000443,275,672,000431,007,281,000397,084,758,770394,182,301,740412,791,234,930434,352,380,160467,465,120,990502,918,586,610537,181,974,040511,335,343,000547,335,708,000606,584,945,000684,351,099,000748,526,708,000719,375,756,000774,800,812,000
Net income
61.69b
-5.15%
8,761,048,0006,433,178,00010,918,718,0005,600,272,000-9,803,596,000-20,393,601,0002,274,880,2701,446,877,4801,961,427,000-10,933,544,000-742,474,3808,056,888,860-25,275,016,000-15,275,470,000-919,176,00031,891,679,00037,006,334,00065,040,121,00061,688,754,000
CFO
96.40b
+21.42%
14,818,649,000-1,347,997,000-11,118,758,000-11,679,166,000-18,183,738,20064,214,781,68018,724,504,4407,279,097,730-4,174,929,9206,738,635,67033,450,172,29052,109,932,81055,531,085,00063,054,367,00018,123,982,00056,764,439,00087,157,236,00079,391,872,00096,396,463,000
Dividend
Dec 27, 2024450 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Headquartered in Seoul, South Korea, JW Pharmaceutical Corporation is a long-standing entity, established in 1945, specializing in the research, production, and global distribution of a comprehensive range of pharmaceuticals and medical supplies. The company's diverse product portfolio serves markets in Japan and numerous other international regions, addressing a broad spectrum of therapeutic areas including cardiovascular health, gastrointestinal and urinary conditions, central nervous system disorders, infectious diseases, women's health, kidney ailments, respiratory issues, oncology, pain management, and critical care nutrition.
URL
https://www.jw-pharma.co.kr/
IPO date
Jun 14, 1976
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT